The ISH Council would like to acknowledge the assistance of the following Corporate Members who are participating in the ISH and therefore helping to promote the advancement of scientific research and knowledge in hypertension and associated cardiovascular diseases.
Current Corporate Members
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit: daiichisankyo.com.
By looking beyond the technology, our real commitment lies in building healthy lives. We aim to provide a total healthcare management service, aimed at preventing and improving such increasingly common health problems as hypertension, respiratory problems, diabetes and obesity.